News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
828,114 Results
Type
Article (85410)
Company Profile (695)
Press Release (742009)
Section
Business (231867)
Career Advice (4103)
Deals (39640)
Drug Delivery (115)
Drug Development (90538)
Employer Resources (194)
FDA (17900)
Job Trends (17266)
News (394876)
Policy (39580)
Tag
Academia (2972)
Alliances (56365)
Alzheimer's disease (1314)
Approvals (17840)
Artificial intelligence (125)
Bankruptcy (394)
Best Places to Work (12421)
Biotechnology (480)
Breast cancer (101)
Cancer (984)
Career advice (3510)
Cell therapy (250)
Clinical research (71213)
Collaboration (351)
Compensation (159)
COVID-19 (2783)
C-suite (87)
Cystic fibrosis (84)
Data (952)
Diabetes (112)
Diagnostics (6589)
Earnings (94067)
Employer resources (166)
Events (126071)
Executive appointments (254)
FDA (18298)
Funding (293)
Gene therapy (184)
GLP-1 (633)
Government (5018)
Healthcare (20627)
Infectious disease (2847)
Inflammatory bowel disease (120)
Interviews (807)
IPO (17530)
Job creations (5177)
Job search strategy (2854)
Layoffs (482)
Legal (10013)
Lung cancer (158)
Manufacturing (172)
Medical device (14243)
Medtech (14248)
Mergers & acquisitions (22027)
Metabolic disorders (367)
Neuroscience (1568)
NextGen Class of 2024 (7644)
Non-profit (5046)
Northern California (1292)
Obesity (203)
Opinion (243)
Patents (94)
People (63981)
Pharmaceutical (136)
Phase I (21931)
Phase II (30945)
Phase III (23316)
Pipeline (403)
Podcasts (88)
Postmarket research (3533)
Preclinical (9919)
Radiopharmaceuticals (242)
Rare diseases (202)
Real estate (7367)
Regulatory (25786)
Research institute (2637)
Resumes & cover letters (648)
Southern California (1137)
Startups (4271)
United States (12116)
Vaccines (613)
Weight loss (174)
Date
Today (141)
Last 7 days (776)
Last 30 days (3085)
Last 365 days (35168)
2024 (31782)
2023 (42566)
2022 (53928)
2021 (58726)
2020 (57671)
2019 (51341)
2018 (39125)
2017 (37191)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1261)
Arizona (212)
Asia (49187)
Australia (8675)
California (2953)
Canada (1054)
China (226)
Colorado (93)
Connecticut (117)
Europe (112600)
Florida (336)
Illinois (327)
Indiana (180)
Kansas (103)
Maryland (566)
Massachusetts (2480)
Michigan (139)
Minnesota (243)
New Jersey (856)
New York (830)
North Carolina (778)
Northern California (1292)
Ohio (117)
Pennsylvania (707)
South America (1646)
Southern California (1137)
Texas (371)
Washington State (345)
828,114 Results for "2seventy bio".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cell Therapy
As 2seventy Nears Breakeven, CEO Chip Baird Explains How the Team Survived
To say that 2seventy bio’s short two years of existence have been dramatic is an understatement. CEO Chip Baird told
BioSpace
transparency and a committed staff have kept the biotech going through thick and thin.
October 2, 2024
·
8 min read
·
Annalee Armstrong
Genetown
2seventy bio to Participate in Upcoming Investor Conferences - May 23, 2024
2seventy bio, Inc . (Nasdaq: TSVT) announced today that members of the management team will present at the following upcoming investor conferences.
May 23, 2024
·
1 min read
Deals
2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million
2seventy bio, Inc., announced the completion of an asset purchase agreement by Novo Nordisk. Under the terms of the APA, Novo Nordisk has acquired the Hemophilia A program and rights to 2seventy’s in vivo gene editing technology outside of oncology and gene editing for autologous or allogeneic cell therapies of immune cells for the treatment of autoimmune disease.
June 26, 2024
·
4 min read
Press Releases
2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress
November 12, 2024
·
19 min read
Business
2seventy bio Reports First Quarter 2024 Financial Results and Recent Operational Progress
2seventy bio, Inc., reported financial results and recent highlights for the first quarter ended March 31, 2024.
May 8, 2024
·
22 min read
Press Releases
2seventy bio to Report Third Quarter 2024 Financial Results and Participate in Upcoming Investor Conference
November 4, 2024
·
1 min read
Business
2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024
2seventy bio, Inc. (Nasdaq: TSVT) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024.
May 3, 2024
·
1 min read
Genetown
2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron
2seventy bio, Inc., announced the completion of the asset purchase agreement by Regeneron Pharmaceuticals, Inc. Under the terms of the APA, Regeneron has acquired all oncology and autoimmune research and development programs and has hired approximately 160 employees from 2seventy bio as part of their newly launched cell medicines business.
April 1, 2024
·
4 min read
Genetown
2seventy bio to Participate in Upcoming February 2024 Investor Conferences
2seventy bio, Inc., announced that members of the management team will present at the following upcoming investor conferences.
February 5, 2024
·
1 min read
Business
2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors
2seventy bio, Inc., announced that Eli Casdin, Chief Investment Officer, and Founder of Casdin Capital, and Charles Newton, Chief Financial Officer, Lyell Immunopharma, have been appointed as new independent members of the Company’s Board of Directors, effective immediately.
March 20, 2024
·
9 min read
1 of 82,812
Next